{
  "id": 565,
  "text": "A complete or partial response was observed in $9 0 .2 \\%$ of patients with FIGO stage IB1.No cases of grade 3 or 4 hematological or gastrointestinal toxicity were observed.After 8 years of follow-up, the OS was not statistically significant between the control group and the NACT group.",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: A complete or partial response was observed in $9 0 .2 \\%$ of patients with FIGO stage IB1.No cases of grade 3 or 4 hematological or gastrointestinal toxicity were observed.After 8 years of follow-up, the OS was not statistically significant between the control group and the NACT group.\n\n<question>: \n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n",
  "ChatGPT_response_0": "对于FIGO IB1期宫颈癌患者使用新辅助化疗（NACT）的长期疗效与安全性结果，研究表明，90.2%的患者显示出完全或部分响应。在随访8年后，整体生存率（OS）方面，对照组与NACT组之间无统计学显著差异。此外，在此治疗过程中，无3级或4级的血液学或胃肠道毒性出现。这意味着NACT在这种特定情况下可能是一个相对安全的治疗选择，并且在长期生存方面与传统治疗方法没有显著区别。",
  "query": "什么是FIGO IB1期患者使用NACT治疗的长期疗效和安全性结果？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 什么是FIGO IB1期患者使用NACT治疗的长期疗效和安全性结果？\n\n<reference text>: A complete or partial response was observed in $9 0 .2 \\%$ of patients with FIGO stage IB1.No cases of grade 3 or 4 hematological or gastrointestinal toxicity were observed.After 8 years of follow-up, the OS was not statistically significant between the control group and the NACT group.\n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n\n<reply>: ",
  "response": "对于FIGO IB1期宫颈癌患者使用新辅助化疗（NACT）的长期疗效与安全性结果，研究表明，90.2%的患者显示出完全或部分响应。在随访8年后，整体生存率（OS）方面，对照组与NACT组之间无统计学显著差异。此外，在此治疗过程中，无3级或4级的血液学或胃肠道毒性出现。这意味着NACT在这种特定情况下可能是一个相对安全的治疗选择，并且在长期生存方面与传统治疗方法没有显著区别。"
}